What is the ACTU stock price?

Actuate Therapeutics, Inc. (ACTU) last available close: $0.4752, as of 10/23/26. Prices on Cylvex may be delayed.

How many analyst price targets for ACTU were reached?

0 of 1 published price targets for ACTU were reached within 12 months (0% reached); 0 are still open. Counts only — firm names and target values are shown to signed-in members.

How many firms publish price targets or ratings on ACTU?

1 firm has published price targets or ratings on ACTU that Cylvex tracks. Counts only — firm names and target values are shown to signed-in members.

Is this investment advice?

No. Cylvex is an educational and informational platform; nothing on this page is investment, financial or trading advice. Past analyst targets do not predict future results.

ACTU

Actuate Therapeutics, Inc. · NASDAQ

News

1 latest

No direct coverage yet · Showing articles that mention ACTU

Thu, Oct 8

Zacks Investment Research10/8/26

AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer

AbbVie announced that its investigational antibody-drug conjugate Temab-A (telisotuzumab adizutecan) has received two FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer. The designations were based on data from the M21-404 study, and the company is evaluating Temab-A across multiple advanced solid tumors as part of its expanding oncology pipeline.

ABBV BMY CRSP

Headlines link to the publisher. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h

Replies 24h

Watchers

Board · $ACTU · 0 threads

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.